The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy

Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (T...

Full description

Saved in:
Bibliographic Details
Published inNeurotherapeutics Vol. 15; no. 2; pp. 324 - 335
Main Authors Raffaelli, Bianca, Reuter, Uwe
Format Journal Article
LanguageEnglish
Published Cham Elsevier Inc 01.04.2018
Springer International Publishing
Springer Nature B.V
Subjects
Online AccessGet full text
ISSN1878-7479
1933-7213
1878-7479
DOI10.1007/s13311-018-0622-7

Cover

Abstract Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood–brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease.
AbstractList Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood–brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease.
Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood-brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease.Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood-brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease.
Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). As reviewed in this article, all 4 antibodies have been proven effective, tolerable, and safe as migraine prophylactic treatments in phase II clinical trials. The mean decrease in migraine days per month was between 3.4 and 6.3 days/month after 8 to 12 weeks of treatment, and the placebo subtracted benefit ranged from 1 to 2.18 days. Notably, up to 32% of subjects experienced total migraine freedom after drug administration. Substance class-specific adverse events and treatment-related serious adverse event did not occur. Further long-term and large-scale trials are currently under way to verify the safety and efficacy profile of mAbs. In particular, the potential risk of vascular adverse events and the role of anti-drug antibodies deserve special attention. Anti-CGRP peptide and anti-CGRP receptor antibodies are the first effective treatments, which were specifically developed for the prevention of migraine. Their site of action in migraine prevention is most likely peripheral due to large molecule size, which prevents the penetration through the blood–brain barrier and thereby shows that peripheral components play a pivotal role in the pathophysiology of a CNS disease.
Author Raffaelli, Bianca
Reuter, Uwe
Author_xml – sequence: 1
  givenname: Bianca
  surname: Raffaelli
  fullname: Raffaelli, Bianca
  organization: Department of Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
– sequence: 2
  givenname: Uwe
  orcidid: 0000-0002-8527-0725
  surname: Reuter
  fullname: Reuter, Uwe
  email: uwe.reuter@charite.de
  organization: Department of Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29616494$$D View this record in MEDLINE/PubMed
BookMark eNqNkc1u1DAUhSNURH_gAdggS2zYBPwTxzELpDJqC1IrKlTWlse5mXHx2MFOivL29SgDLV2MWMVSvu_6-Nzj4sAHD0XxmuD3BGPxIRHGCCkxaUpcU1qKZ8URaURTikrIg0fnw-I4pVuMOWOyeVEcUlmTupLVUdHfrAF9tsGF1YRCh66CD8YFrx069YNdhtZC-ojOgxkTCh4ttDN2CN56dAEeyu_g9AAtuoZ-sC2gLkR0HUO_npw2gzXoyq6ith5QvijqfnpZPO-0S_Bq9z0pfpyf3Sy-lJffLr4uTi9Lw6t6KGXHqSY1I83SYCoFSMkEM0ANqXjVckGXYISsOgZ1yxvaci6xrDUzXc0o1-ykoPPc0fd6-q2dU320Gx0nRbDa1qfm-lSuT23rUyJLn2apH5cbaA34IeoHMWir_v3j7Vqtwp3ikvGakzzg3W5ADL9GSIPa2GTAOe0hjElRTIlghFVb9O0T9DaMMRc_U0RQJrfUm8eJ_kb5s8EMiBkwMaQUoVN5P3qwYRvQur2PJU_M_ylo12rKrF9BfAi9T5KzBHnfdzZLxllvjXY_YVJtsHvce5UL4PQ
CitedBy_id crossref_primary_10_1016_j_nbd_2020_105157
crossref_primary_10_1002_prp2_567
crossref_primary_10_1016_j_jpain_2024_03_010
crossref_primary_10_1080_14740338_2021_1942839
crossref_primary_10_1007_s12325_021_01632_x
crossref_primary_10_1111_head_13956
crossref_primary_10_3390_jcm13175156
crossref_primary_10_2174_1871527319666200618144637
crossref_primary_10_52965_001c_35506
crossref_primary_10_3389_fphys_2021_820006
crossref_primary_10_3390_pharmaceutics12121180
crossref_primary_10_1111_head_14013
crossref_primary_10_1124_mol_119_116954
crossref_primary_10_1097_WNO_0000000000000837
crossref_primary_10_1186_s10194_020_01105_6
crossref_primary_10_1016_j_clinthera_2022_01_006
crossref_primary_10_1177_0333102419840780
crossref_primary_10_4103_sjmms_sjmms_95_22
crossref_primary_10_1007_s40267_020_00801_2
crossref_primary_10_31616_asj_2023_0121
crossref_primary_10_1186_s10194_024_01717_2
crossref_primary_10_3389_fpain_2021_705276
crossref_primary_10_1186_s10194_020_01143_0
crossref_primary_10_1007_s11916_019_0768_y
crossref_primary_10_1080_07853890_2021_2014556
crossref_primary_10_17925_ENR_2019_14_2_68
crossref_primary_10_2139_ssrn_3791424
crossref_primary_10_1186_s10194_019_0979_y
crossref_primary_10_1111_head_13510
crossref_primary_10_52965_001c_38534
crossref_primary_10_48208_HeadacheMed_2023_16
crossref_primary_10_17116_pain20242202156
crossref_primary_10_24304_kjcp_2019_29_2_71
crossref_primary_10_52965_001c_38439
crossref_primary_10_3389_fphys_2018_01249
crossref_primary_10_1007_s40267_019_00680_2
crossref_primary_10_1111_ene_14102
crossref_primary_10_1177_0333102419877169
crossref_primary_10_1080_17512433_2020_1774361
crossref_primary_10_48208_HeadacheMed_2023_29
crossref_primary_10_1177_0333102420946725
crossref_primary_10_1007_s10787_023_01276_z
crossref_primary_10_3390_ijms21176045
crossref_primary_10_1208_s12248_020_00443_2
crossref_primary_10_1097_WNF_0000000000000571
crossref_primary_10_1177_0333102420905132
crossref_primary_10_3390_neurolint16010019
crossref_primary_10_1016_j_pharep_2019_03_002
crossref_primary_10_1111_head_13414
crossref_primary_10_1111_head_13691
crossref_primary_10_1007_s40122_020_00159_3
Cites_doi 10.1002/ana.410280213
10.1056/NEJMcp1605502
10.1111/j.1365-2796.1990.tb00236.x
10.1056/NEJM198203043060906
10.1016/S1474-4422(14)70209-1
10.1038/nrneurol.2010.127
10.1016/j.pharmthera.2005.04.010
10.1056/NEJMoa1709038
10.1007/s11916-015-0476-1
10.1177/0333102414547138
10.1016/S1474-4422(14)70128-0
10.1212/WNL.0000000000002801
10.1016/S1474-4422(14)70126-7
10.1212/WNL.0000000000000771
10.1517/17460441.2013.826644
10.1016/S1474-4422(14)70228-5
10.1016/j.ymeth.2005.02.001
10.1002/ana.410330109
10.1007/s11739-016-1489-4
10.1177/0333102413517775
10.1212/01.wnl.0000252808.97649.21
10.1002/ana.410230214
10.1046/j.1468-2982.2002.00310.x
10.1016/S1474-4422(15)00249-5
10.1212/WNL.0000000000004391
10.1111/bcp.12591
10.1016/j.coph.2008.12.007
10.1038/304129a0
10.1016/S1474-4422(17)30083-2
10.1097/WCO.0b013e3283466c8e
10.1124/jpet.115.227793
10.1056/NEJMoa030505
10.1016/j.clpt.2004.10.001
10.1038/bjp.2008.334
10.1016/S1474-4422(16)00019-3
10.1177/0333102416650702
10.1016/j.tips.2016.06.002
10.1016/S1474-4422(15)00245-8
10.1152/physrev.00034.2015
10.1056/NEJMoa1705848
10.1016/S1474-4422(16)00040-5
10.1212/WNL.0b013e3182a6cb72
10.1097/WCO.0000000000000438
10.1056/NEJMra010917
10.1001/jamaneurol.2017.3859
ContentType Journal Article
Copyright 2018 The American Society for Experimental NeuroTherapeutics, Inc.
The American Society for Experimental NeuroTherapeutics, Inc. 2018
Neurotherapeutics is a copyright of Springer, (2018). All Rights Reserved.
Copyright_xml – notice: 2018 The American Society for Experimental NeuroTherapeutics, Inc.
– notice: The American Society for Experimental NeuroTherapeutics, Inc. 2018
– notice: Neurotherapeutics is a copyright of Springer, (2018). All Rights Reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7RV
7TK
7X7
7XB
88E
88G
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
K9.
KB0
M0S
M1P
M2M
NAPCQ
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
Q9U
7X8
5PM
ADTOC
UNPAY
DOI 10.1007/s13311-018-0622-7
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Psychology Database (Alumni)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Medical Database
Psychology Database
Nursing & Allied Health Premium
Proquest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest One Psychology
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Central Basic
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Psychology Journals (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest Psychology Journals
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
MEDLINE

ProQuest One Psychology
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1878-7479
EndPage 335
ExternalDocumentID 10.1007/s13311-018-0622-7
PMC5935651
29616494
10_1007_s13311_018_0622_7
S1878747923015647
Genre Journal Article
Review
GroupedDBID ---
--K
.1-
.FO
06D
0R~
0VY
123
1B1
203
29~
2JY
2KG
2KM
2VQ
30V
4.4
406
408
40E
53G
5VS
67N
71M
7RV
7X7
88E
8AO
8FI
8FJ
8UJ
96X
AAAVM
AABHQ
AAEDT
AAFWJ
AAHNG
AAIAL
AAJBT
AAJKR
AAKDD
AALRI
AANXM
AANZL
AAQFI
AARHV
AARTL
AATVU
AAUYE
AAWCG
AAXUO
AAYIU
AAYQN
AAYTO
AAYWO
AAYZH
AAZMS
ABDZT
ABECU
ABFSG
ABFTV
ABIPD
ABIVO
ABJOX
ABKCH
ABMQK
ABPLI
ABQBU
ABSXP
ABTEG
ABTHY
ABTKH
ABTMW
ABUWG
ABWVN
ABXPI
ACGFS
ACHSB
ACKNC
ACMDZ
ACMLO
ACOKC
ACPRK
ACRPL
ACSTC
ACVFH
ADBBV
ADCNI
ADHIR
ADJJI
ADKNI
ADKPE
ADMUD
ADNMO
ADRFC
ADTPH
ADURQ
ADVLN
ADYFF
ADZKW
AEBTG
AEGNC
AEJHL
AEJRE
AEKER
AENEX
AEOHA
AEPYU
AESKC
AETCA
AEUPX
AEVLU
AEXYK
AEZWR
AFBBN
AFHIU
AFJKZ
AFKRA
AFLOW
AFPKN
AFPUW
AFQWF
AFRHN
AFWTZ
AFZKB
AGAYW
AGDGC
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHPBZ
AHSBF
AHWEU
AHYZX
AIAKS
AIGII
AIIXL
AILAN
AITGF
AITUG
AIXLP
AJBLW
AJRNO
AJUYK
AJZVZ
AKBMS
AKMHD
AKRWK
AKYEP
ALFXC
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMRAJ
AMXSW
AMYLF
ANMIH
AOCGG
AOIJS
APXCP
ASPBG
ATHPR
AVWKF
AXYYD
AYFIA
AZFZN
AZQEC
BENPR
BGNMA
BKEYQ
BMSDO
BPHCQ
BVXVI
CCPQU
CS3
CSCUP
DDRTE
DNIVK
DPUIP
DU5
DWQXO
DX2
EBS
EIOEI
EJD
EN4
EO8
EO9
EP2
EP3
ESBYG
EX3
F5P
FDB
FEDTE
FERAY
FFXSO
FINBP
FNLPD
FNPLU
FRRFC
FSGXE
FYUFA
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ7
GROUPED_DOAJ
H13
HF~
HMCUK
HMJXF
HRMNR
HVGLF
HYE
HZ~
I0C
IHE
IKXTQ
IMOTQ
ITM
IWAJR
J-C
JBSCW
JZLTJ
KOV
LLZTM
M1P
M2M
M41
M4Y
MO0
NAPCQ
NPVJJ
NQ-
NQJWS
NU0
O9-
O93
O9I
O9J
OK1
OZT
PHGZM
PHGZT
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PSYQQ
PUEGO
R9I
RLLFE
ROL
RPM
RPZ
RSV
S1Z
S27
S3A
S3B
SBL
SDG
SHX
SISQX
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
T13
TSG
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VFIZW
W48
WK8
WOW
Z5R
ZMTXR
ZOVNA
~A9
-56
-5G
-BR
-EM
-~C
04C
2JN
3V.
ABAKF
ABULA
ACZOJ
ADINQ
AEFQL
AFCTW
ALIPV
EIHBH
GQ6
RIG
SV3
Z7U
Z83
Z87
AAYXX
CITATION
EBLON
~HD
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c546t-9f52a16318bc0297e99373ce2c1454d572bec794f3e6d582d559096a3cf6325a3
IEDL.DBID 7X7
ISSN 1878-7479
1933-7213
IngestDate Tue Aug 26 13:26:51 EDT 2025
Tue Sep 30 16:59:59 EDT 2025
Sat Sep 27 23:51:00 EDT 2025
Wed Aug 13 07:15:00 EDT 2025
Thu Apr 03 07:04:02 EDT 2025
Wed Oct 01 02:56:10 EDT 2025
Thu Apr 24 22:57:42 EDT 2025
Fri Feb 21 02:34:38 EST 2025
Tue Aug 26 20:09:50 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Efficacy
Tolerability
Safety
Migraine
Language English
License http://www.elsevier.com/open-access/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c546t-9f52a16318bc0297e99373ce2c1454d572bec794f3e6d582d559096a3cf6325a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Literature Review-3
ObjectType-Review-3
content type line 23
ORCID 0000-0002-8527-0725
OpenAccessLink https://proxy.k.utb.cz/login?url=https://link.springer.com/content/pdf/10.1007/s13311-018-0622-7.pdf
PMID 29616494
PQID 2021172391
PQPubID 1476362
PageCount 12
ParticipantIDs unpaywall_primary_10_1007_s13311_018_0622_7
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5935651
proquest_miscellaneous_2021731341
proquest_journals_2021172391
pubmed_primary_29616494
crossref_citationtrail_10_1007_s13311_018_0622_7
crossref_primary_10_1007_s13311_018_0622_7
springer_journals_10_1007_s13311_018_0622_7
elsevier_clinicalkey_doi_10_1007_s13311_018_0622_7
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2018-04-01
PublicationDateYYYYMMDD 2018-04-01
PublicationDate_xml – month: 04
  year: 2018
  text: 2018-04-01
  day: 01
PublicationDecade 2010
PublicationPlace Cham
PublicationPlace_xml – name: Cham
– name: United States
– name: New York
PublicationSubtitle The Journal of the American Society for Experimental NeuroTherapeutics
PublicationTitle Neurotherapeutics
PublicationTitleAbbrev Neurotherapeutics
PublicationTitleAlternate Neurotherapeutics
PublicationYear 2018
Publisher Elsevier Inc
Springer International Publishing
Springer Nature B.V
Publisher_xml – name: Elsevier Inc
– name: Springer International Publishing
– name: Springer Nature B.V
References Shi, Lehto, Zhu (bib52) 2016; 356
Alder Biopharmaceuticals, Inc. Evaluation of ALD403 (eptinezumab) in the prevention of chronic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02974153. Accessed 29 August 2017.
Ho, Ho, Ge (bib23) 2014; 83
Goadsby, Edvinsson (bib16) 1993; 33
Rosenfeld, Mermod, Amara (bib8) 1983; 304
Bigal, Edvinsson, Rapoport (bib47) 2015; 14
Goadsby, Edvinsson, Ekman (bib9) 1988; 23
Eli Lilly and Company. A study of LY2951742 in healthy Japanese and Caucasian participants. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02104765. Accessed 29 August 2017.
Petersen, Lassen, Birk, Lesko, Olesen (bib22) 2005; 77
Giamberardino, Affaitati, Curto (bib3) 2016; 11
Miller, Maloney, Warnke, Levy (bib26) 1982; 306
Alder Biopharmaceuticals, Inc. A multicenter assessment of ALD403 in frequent episodic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02559895. Accessed 29 August 2017.
Eli Lilly and Company. A study of LY2951742 in healthy volunteers. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT01337596. Accessed 29 August 2017.
De Hoon, Van Hecken, Vandermeulen, Yan, Vu, Vargas (bib53) 2017
Dodick, Goadsby, Silberstein (bib33) 2017; 88
Cernuda-Morollon, Larrosa, Ramon (bib17) 2013; 81
Dodick, Goadsby, Spierings (bib39) 2014; 13
Teva Branded Pharmaceutical Products, R&D Inc. Efficacy and safety of subcutaneous administration of TEV-48125 for the preventive treatment of migraine. Available at: https://clinicaltrials.gov/ct2/show/NCT02638103. Accessed 29 August 2017.
Edvinsson, Goadsby (bib13) 1990; 228
Bigal, Escandon, Bronson (bib29) 2014; 34
Skljarevski V, Oakes TM, Zhang Q, et al., Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2017. doi: https://doi.org/10.1001/jamaneurol.2017.385.
Bigal, Dodick, Rapoport (bib46) 2015; 14
Bigal, Dodick, Krymchantowski (bib48) 2016; 87
Benemei, Nicoletti, Capone, Geppetti (bib21) 2009; 9
Labruijere, Ibrahimi, Chan, MaassenVanDenBrink (bib24) 2013; 8
Hepp, Dodick, Varon (bib2) 2015; 35
Eli Lilly and Company. A study of LY2951742 in healthy participants. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02576951. Accessed 29 August 2017.
Ho, Edvinsson, Goadsby (bib10) 2010; 6
Amgen. Study to evaluate the effect on blood pressure of AMG 334 given concomitantly with subcutaneous sumatriptan. 2017. Available at: https://clinicaltrials.gov/ct2/show/NTC02741310. Accessed 29 August 2017.
Goadsby, Reuter, Hallström (bib59) 2017; 377
Olesen, Diener, Husstedt (bib12) 2004; 350
Goadbsy, Lipton, Ferrari (bib7) 2002; 346
Pellesi, Guerzoni, Pini (bib30) 2017; 00
Bigal, Walter, Rapoport (bib28) 2015; 79
Silberstein, Dodick, Bigal (bib50) 2017; 377
Ramadan, Buchanan (bib4) 2006; 112
Teva Branded Pharmaceutical Products, R&D Inc. Efficacy and safety of 2 dose regimens of TEV-48125 versus placebo for the preventive treatment of episodic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02629861. Accessed 29 August 2017.
Sun, Dodick, Silberstein (bib55) 2016; 15
Goadsby, Holland, Martins-Oliveira (bib6) 2017; 97
Eli Lilly and Company. A safety study of LY2951742 in participants with migraine, with or without aura. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614287. Accessed 29 August 2017.
Baker B, Hodsman P, Smith J. PK & PD supporting a single dose, placebo-controlled randomized ascending dose study of ALD403, a humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered IV or SC. Available at: http://www.alderbio.com/wp-content/uploads/2016/08/ALD403-EHMTIC-Poster-Baker-29-August-2016-Portrait-WO-QR-Code.pdf. Accessed 29 August 2017.
Ramos, Pascual (bib14) 2016; 15
Reuter (bib25) 2014; 13
Amgen. A study to assess the long-term safety and efficacy of AMG 334 in chronic migraine prevention. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02174861. Accessed 29 August 2017.
Dodick, Ashina, Kudrow (bib58) 2017; e1
Dodick, Goadsby, Silberstein (bib31) 2014; 13
MaassenVanDenBrink, Meijer, Villalón, Ferrari (bib11) 2016; 37
Eli Lilly and Company. Evaluation of LY2951742 in the prevention of episodic migraine—the EVOLVE-1 study. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614183. Accessed 29 August 2017.
Diener (bib63) 2014; 13
Charles (bib62) 2017; 377
Lipton, Bigal, Diamond (bib1) 2007; 68
Eli Lilly and Company. Evaluation of LY2951742 in the prevention of chronic migraine (REGAIN). 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614261. Accessed 29 August 2017.
Ashina, Dodick, Goadsby (bib56) 2017; 89
Tepper, Ashina, Reuter (bib57) 2017; 16
Zeller, Poulsen, Sutton (bib64) 2008; 155
Gracia-Naya, Santos-Lasaosa, Rios-Gomez (bib5) 2011; 53
Walter, Bigal (bib45) 2015; 19
Eli Lilly and Company. Evaluation of LY2951742 in the prevention of episodic migraine—the EVOLVE-2 Study. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614196. Accessed 29 August 2017.
Lassen, Haderslev, Jacobsen (bib18) 2002; 22
Noseda, Burstein (bib19) 2011; 24
Kopruszinski, Xie, Eyde (bib20) 2016; 37
Goadsby, Edvinsson, Ekman (bib15) 1990; 28
Wu, Dall'Acqua (bib27) 2005; 36
Mitsikostas, Reuter (bib61) 2017; 30
Labruijere, Ibrahimi, Chan, MaassenVanDenBrink (CR24) 2013; 8
Dodick, Goadsby, Silberstein (CR31) 2014; 13
Bigal, Escandon, Bronson (CR29) 2014; 34
Tepper, Ashina, Reuter (CR57) 2017; 16
Silberstein, Dodick, Bigal (CR50) 2017; 377
CR38
Hepp, Dodick, Varon (CR2) 2015; 35
CR37
CR36
CR35
CR34
Dodick, Goadsby, Silberstein (CR33) 2017; 88
CR32
Walter, Bigal (CR45) 2015; 19
Bigal, Walter, Rapoport (CR28) 2015; 79
Benemei, Nicoletti, Capone, Geppetti (CR21) 2009; 9
Shi, Lehto, Zhu (CR52) 2016; 356
Goadsby, Edvinsson, Ekman (CR9) 1988; 23
Olesen, Diener, Husstedt (CR12) 2004; 350
Goadsby, Reuter, Hallström (CR59) 2017; 377
Wu, Dall’Acqua (CR27) 2005; 36
Lassen, Haderslev, Jacobsen (CR18) 2002; 22
Bigal, Dodick, Krymchantowski (CR48) 2016; 87
Cernuda-Morollon, Larrosa, Ramon (CR17) 2013; 81
Petersen, Lassen, Birk, Lesko, Olesen (CR22) 2005; 77
CR49
Gracia-Naya, Santos-Lasaosa, Rios-Gomez (CR5) 2011; 53
Kopruszinski, Xie, Eyde (CR20) 2016; 37
CR44
CR43
Ho, Edvinsson, Goadsby (CR10) 2010; 6
CR42
CR41
CR40
Pellesi, Guerzoni, Pini (CR30) 2017; 00
Miller, Maloney, Warnke, Levy (CR26) 1982; 306
Ramos, Pascual (CR14) 2016; 15
Ho, Ho, Ge (CR23) 2014; 83
Ramadan, Buchanan (CR4) 2006; 112
Mitsikostas, Reuter (CR61) 2017; 30
Zeller, Poulsen, Sutton (CR64) 2008; 155
Giamberardino, Affaitati, Curto (CR3) 2016; 11
Edvinsson, Goadsby (CR13) 1990; 228
Goadsby, Edvinsson (CR16) 1993; 33
Noseda, Burstein (CR19) 2011; 24
Charles (CR62) 2017; 377
CR54
CR53
MaassenVanDenBrink, Meijer, Villalón, Ferrari (CR11) 2016; 37
Reuter (CR25) 2014; 13
CR51
Sun, Dodick, Silberstein (CR55) 2016; 15
Rosenfeld, Mermod, Amara (CR8) 1983; 304
Dodick, Goadsby, Spierings (CR39) 2014; 13
Dodick, Ashina, Kudrow (CR58) 2017; e1
Diener (CR63) 2014; 13
Goadbsy, Lipton, Ferrari (CR7) 2002; 346
Goadsby, Edvinsson, Ekman (CR15) 1990; 28
Bigal, Edvinsson, Rapoport (CR47) 2015; 14
Bigal, Dodick, Rapoport (CR46) 2015; 14
Lipton, Bigal, Diamond (CR1) 2007; 68
CR60
Goadsby, Holland, Martins-Oliveira (CR6) 2017; 97
Ashina, Dodick, Goadsby (CR56) 2017; 89
Walter (10.1007/s13311-018-0622-7_bib45) 2015; 19
Rosenfeld (10.1007/s13311-018-0622-7_bib8) 1983; 304
Ho (10.1007/s13311-018-0622-7_bib23) 2014; 83
Mitsikostas (10.1007/s13311-018-0622-7_bib61) 2017; 30
Cernuda-Morollon (10.1007/s13311-018-0622-7_bib17) 2013; 81
Petersen (10.1007/s13311-018-0622-7_bib22) 2005; 77
10.1007/s13311-018-0622-7_bib36
10.1007/s13311-018-0622-7_bib37
10.1007/s13311-018-0622-7_bib34
10.1007/s13311-018-0622-7_bib35
Hepp (10.1007/s13311-018-0622-7_bib2) 2015; 35
Ashina (10.1007/s13311-018-0622-7_bib56) 2017; 89
Benemei (10.1007/s13311-018-0622-7_bib21) 2009; 9
10.1007/s13311-018-0622-7_bib38
Goadsby (10.1007/s13311-018-0622-7_bib16) 1993; 33
10.1007/s13311-018-0622-7_bib32
Goadsby (10.1007/s13311-018-0622-7_bib59) 2017; 377
Dodick (10.1007/s13311-018-0622-7_bib31) 2014; 13
Lipton (10.1007/s13311-018-0622-7_bib1) 2007; 68
Ramos (10.1007/s13311-018-0622-7_bib14) 2016; 15
Ramadan (10.1007/s13311-018-0622-7_bib4) 2006; 112
Diener (10.1007/s13311-018-0622-7_bib63) 2014; 13
Bigal (10.1007/s13311-018-0622-7_bib47) 2015; 14
Goadbsy (10.1007/s13311-018-0622-7_bib7) 2002; 346
Labruijere (10.1007/s13311-018-0622-7_bib24) 2013; 8
Kopruszinski (10.1007/s13311-018-0622-7_bib20) 2016; 37
Ho (10.1007/s13311-018-0622-7_bib10) 2010; 6
MaassenVanDenBrink (10.1007/s13311-018-0622-7_bib11) 2016; 37
10.1007/s13311-018-0622-7_bib49
10.1007/s13311-018-0622-7_bib40
Wu (10.1007/s13311-018-0622-7_bib27) 2005; 36
10.1007/s13311-018-0622-7_bib43
Shi (10.1007/s13311-018-0622-7_bib52) 2016; 356
10.1007/s13311-018-0622-7_bib44
10.1007/s13311-018-0622-7_bib41
Bigal (10.1007/s13311-018-0622-7_bib48) 2016; 87
10.1007/s13311-018-0622-7_bib42
Tepper (10.1007/s13311-018-0622-7_bib57) 2017; 16
Dodick (10.1007/s13311-018-0622-7_bib39) 2014; 13
Lassen (10.1007/s13311-018-0622-7_bib18) 2002; 22
Pellesi (10.1007/s13311-018-0622-7_bib30) 2017; 00
Bigal (10.1007/s13311-018-0622-7_bib46) 2015; 14
Gracia-Naya (10.1007/s13311-018-0622-7_bib5) 2011; 53
Goadsby (10.1007/s13311-018-0622-7_bib15) 1990; 28
Charles (10.1007/s13311-018-0622-7_bib62) 2017; 377
10.1007/s13311-018-0622-7_bib51
Zeller (10.1007/s13311-018-0622-7_bib64) 2008; 155
10.1007/s13311-018-0622-7_bib54
Dodick (10.1007/s13311-018-0622-7_bib33) 2017; 88
Dodick (10.1007/s13311-018-0622-7_bib58) 2017; e1
De Hoon (10.1007/s13311-018-0622-7_bib53) 2017
Goadsby (10.1007/s13311-018-0622-7_bib6) 2017; 97
Bigal (10.1007/s13311-018-0622-7_bib28) 2015; 79
Miller (10.1007/s13311-018-0622-7_bib26) 1982; 306
Sun (10.1007/s13311-018-0622-7_bib55) 2016; 15
Olesen (10.1007/s13311-018-0622-7_bib12) 2004; 350
Bigal (10.1007/s13311-018-0622-7_bib29) 2014; 34
Silberstein (10.1007/s13311-018-0622-7_bib50) 2017; 377
10.1007/s13311-018-0622-7_bib60
Giamberardino (10.1007/s13311-018-0622-7_bib3) 2016; 11
Goadsby (10.1007/s13311-018-0622-7_bib9) 1988; 23
Noseda (10.1007/s13311-018-0622-7_bib19) 2011; 24
Reuter (10.1007/s13311-018-0622-7_bib25) 2014; 13
Edvinsson (10.1007/s13311-018-0622-7_bib13) 1990; 228
References_xml – volume: 89
  start-page: 1237
  year: 2017
  end-page: 1243
  ident: bib56
  article-title: Erenumab (AMG334) in episodic migraine. Interim analysis of an ongoing open-label study
  publication-title: Neurology.
– volume: 37
  start-page: 779
  year: 2016
  end-page: 788
  ident: bib11
  article-title: Wiping out CGRP: potential cardiovascular risks
  publication-title: Trends Pharmacol Sci.
– reference: Eli Lilly and Company. Evaluation of LY2951742 in the prevention of chronic migraine (REGAIN). 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614261. Accessed 29 August 2017.
– volume: 15
  start-page: 382
  year: 2016
  end-page: 390
  ident: bib55
  article-title: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
  publication-title: Lancet Neurol.
– volume: 6
  start-page: 573
  year: 2010
  end-page: 582
  ident: bib10
  article-title: CGRP and its receptors provide new insights into migraine pathophysiology
  publication-title: Nat Rev Neurol.
– volume: 83
  start-page: 958
  year: 2014
  end-page: 966
  ident: bib23
  article-title: Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
  publication-title: Neurology.
– volume: 00
  start-page: 1
  year: 2017
  end-page: 14
  ident: bib30
  article-title: Spotlight on Anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date
  publication-title: Clin Pharmacol Drug Dev.
– reference: Teva Branded Pharmaceutical Products, R&D Inc. Efficacy and safety of subcutaneous administration of TEV-48125 for the preventive treatment of migraine. Available at: https://clinicaltrials.gov/ct2/show/NCT02638103. Accessed 29 August 2017.
– reference: Eli Lilly and Company. Evaluation of LY2951742 in the prevention of episodic migraine—the EVOLVE-1 study. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614183. Accessed 29 August 2017.
– reference: Eli Lilly and Company. A study of LY2951742 in healthy participants. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02576951. Accessed 29 August 2017.
– volume: 37
  start-page: 560
  year: 2016
  end-page: 570
  ident: bib20
  article-title: Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents
  publication-title: Cephalalgia.
– volume: 16
  start-page: 425
  year: 2017
  end-page: 434
  ident: bib57
  article-title: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
  publication-title: Lancet Neurol
– volume: 30
  start-page: 272
  year: 2017
  end-page: 280
  ident: bib61
  article-title: Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies
  publication-title: Curr Opin Neurol.
– reference: Teva Branded Pharmaceutical Products, R&D Inc. Efficacy and safety of 2 dose regimens of TEV-48125 versus placebo for the preventive treatment of episodic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02629861. Accessed 29 August 2017.
– volume: 13
  start-page: 1065
  year: 2014
  end-page: 1067
  ident: bib63
  article-title: CGRP as a new target in prevention and treatment of migraine
  publication-title: Lancet Neurol.
– volume: 14
  start-page: 1091
  year: 2015
  end-page: 1100
  ident: bib47
  article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
  publication-title: Lancet Neurol.
– year: 2017
  ident: bib53
  article-title: Phase 1, randomized, double-blind, placebo-controlled, single-dose and multiple-dose studies of erenumab in healthy subjects and patients with migraine.
  publication-title: Clin Pharmacol Ther.
– volume: 97
  start-page: 553
  year: 2017
  end-page: 622
  ident: bib6
  article-title: Pathophysiology of migraine: a disorder of sensory processing
  publication-title: Physiol Rev.
– volume: 306
  start-page: 517
  year: 1982
  end-page: 522
  ident: bib26
  article-title: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
  publication-title: N Engl J Med.
– volume: 13
  start-page: 885
  year: 2014
  end-page: 892
  ident: bib39
  article-title: Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
  publication-title: Lancet Neurol.
– volume: 87
  start-page: 41
  year: 2016
  end-page: 48
  ident: bib48
  article-title: TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points
  publication-title: Neurology.
– volume: 155
  start-page: 1093
  year: 2008
  end-page: 1103
  ident: bib64
  article-title: CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
  publication-title: Br J Pharmacol.
– volume: 36
  start-page: 1
  year: 2005
  end-page: 2
  ident: bib27
  article-title: Humanized antibodies and their applications
  publication-title: Methods.
– volume: 77
  start-page: 202
  year: 2005
  end-page: 213
  ident: bib22
  article-title: BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation
  publication-title: Clin Pharmacol Ther.
– volume: 11
  start-page: 1045
  year: 2016
  end-page: 1057
  ident: bib3
  article-title: Anti-CGRP monoclonal antibodies in migraine: current perspectives
  publication-title: Intern Emerg Med.
– volume: 53
  start-page: 201
  year: 2011
  end-page: 208
  ident: bib5
  article-title: Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine
  publication-title: Rev Neurol.
– reference: Eli Lilly and Company. Evaluation of LY2951742 in the prevention of episodic migraine—the EVOLVE-2 Study. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614196. Accessed 29 August 2017.
– reference: Baker B, Hodsman P, Smith J. PK & PD supporting a single dose, placebo-controlled randomized ascending dose study of ALD403, a humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody administered IV or SC. Available at: http://www.alderbio.com/wp-content/uploads/2016/08/ALD403-EHMTIC-Poster-Baker-29-August-2016-Portrait-WO-QR-Code.pdf. Accessed 29 August 2017.
– volume: e1
  start-page: 88
  year: 2017
  ident: bib58
  article-title: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the ARISE trial
  publication-title: J Neurol Neurosurg Psychiatry.
– volume: 33
  start-page: 48
  year: 1993
  end-page: 56
  ident: bib16
  article-title: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
  publication-title: Ann Neurol.
– reference: Alder Biopharmaceuticals, Inc. Evaluation of ALD403 (eptinezumab) in the prevention of chronic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02974153. Accessed 29 August 2017.
– volume: 377
  start-page: 553
  year: 2017
  end-page: 561
  ident: bib62
  article-title: Migraine
  publication-title: N Engl J Med.
– volume: 350
  start-page: 1104
  year: 2004
  end-page: 1110
  ident: bib12
  article-title: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
  publication-title: N Engl J Med.
– volume: 68
  start-page: 343
  year: 2007
  end-page: 349
  ident: bib1
  article-title: Migraine prevalence, disease burden, and the need for preventive therapy
  publication-title: Neurology
– volume: 19
  start-page: 6
  year: 2015
  ident: bib45
  article-title: TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine
  publication-title: Curr Pain Headache Rep.
– volume: 13
  start-page: 1100
  year: 2014
  end-page: 1107
  ident: bib31
  article-title: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
  publication-title: Lancet Neurol.
– volume: 79
  start-page: 886
  year: 2015
  end-page: 895
  ident: bib28
  article-title: Therapeutic antibodies against CGRP or its receptor
  publication-title: Br J Clin Pharmacol.
– volume: 9
  start-page: 9
  year: 2009
  end-page: 14
  ident: bib21
  article-title: CGRP receptors in the control of pain and inflammation
  publication-title: Curr Opin Pharmacol.
– volume: 88
  year: 2017
  ident: bib33
  article-title: Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of chronic migraine
  publication-title: Neurology
– volume: 13
  start-page: 857
  year: 2014
  end-page: 859
  ident: bib25
  article-title: Anti-CGRP antibodies: a new approach to migraine prevention
  publication-title: Lancet Neurol.
– volume: 304
  start-page: 129
  year: 1983
  end-page: 135
  ident: bib8
  article-title: Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing
  publication-title: Nature.
– volume: 23
  start-page: 193
  year: 1988
  end-page: 196
  ident: bib9
  article-title: Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system
  publication-title: Ann Neurol.
– reference: Alder Biopharmaceuticals, Inc. A multicenter assessment of ALD403 in frequent episodic migraine. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02559895. Accessed 29 August 2017.
– volume: 34
  start-page: 483
  year: 2014
  end-page: 492
  ident: bib29
  article-title: Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program
  publication-title: Cephalalgia.
– reference: Eli Lilly and Company. A study of LY2951742 in healthy Japanese and Caucasian participants. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02104765. Accessed 29 August 2017.
– volume: 24
  start-page: 197
  year: 2011
  end-page: 202
  ident: bib19
  article-title: Advances in understanding the mechanisms of migraine-type photophobia
  publication-title: Curr Opin Neurol.
– reference: Amgen. A study to assess the long-term safety and efficacy of AMG 334 in chronic migraine prevention. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02174861. Accessed 29 August 2017.
– volume: 15
  start-page: 347
  year: 2016
  end-page: 349
  ident: bib14
  article-title: AMG 334 CGRP antibody for migraine: time to celebrate?
  publication-title: Lancet Neurol.
– reference: Eli Lilly and Company. A study of LY2951742 in healthy volunteers. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT01337596. Accessed 29 August 2017.
– reference: Skljarevski V, Oakes TM, Zhang Q, et al., Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2017. doi: https://doi.org/10.1001/jamaneurol.2017.385.
– volume: 8
  start-page: 1309
  year: 2013
  end-page: 1323
  ident: bib24
  article-title: Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies
  publication-title: Expert Opin Drug Discov.
– volume: 28
  start-page: 183
  year: 1990
  end-page: 187
  ident: bib15
  article-title: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
  publication-title: Ann Neurol.
– volume: 346
  start-page: 257
  year: 2002
  end-page: 270
  ident: bib7
  article-title: Migraine—current understanding and treatment
  publication-title: N Engl J Med.
– volume: 81
  start-page: 1191
  year: 2013
  end-page: 1196
  ident: bib17
  article-title: Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
  publication-title: Neurology.
– volume: 228
  start-page: 299
  year: 1990
  end-page: 304
  ident: bib13
  article-title: Extracerebral manifestations in migraine. A peptidergic involvement?
  publication-title: J Intern Med.
– volume: 356
  start-page: 223
  year: 2016
  end-page: 231
  ident: bib52
  article-title: Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor
  publication-title: J Pharmacol Exp Ther.
– reference: Amgen. Study to evaluate the effect on blood pressure of AMG 334 given concomitantly with subcutaneous sumatriptan. 2017. Available at: https://clinicaltrials.gov/ct2/show/NTC02741310. Accessed 29 August 2017.
– volume: 377
  start-page: 2123
  year: 2017
  end-page: 2132
  ident: bib59
  article-title: A controlled trial of erenumab for episodic migraine
  publication-title: N Engl J Med.
– volume: 35
  start-page: 478
  year: 2015
  end-page: 488
  ident: bib2
  article-title: Adherence to oral migraine-preventive medications among patients with chronic migraine
  publication-title: Cephalalgia.
– volume: 377
  start-page: 2113
  year: 2017
  end-page: 2122
  ident: bib50
  article-title: Fremanezumab for the preventive treatment of chronic migraine
  publication-title: N Engl J Med.
– volume: 14
  start-page: 1081
  year: 2015
  end-page: 1090
  ident: bib46
  article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
  publication-title: Lancet Neurol.
– volume: 22
  start-page: 54
  year: 2002
  end-page: 61
  ident: bib18
  article-title: CGRP may play a causative role in migraine
  publication-title: Cephalalgia.
– volume: 112
  start-page: 199
  year: 2006
  end-page: 212
  ident: bib4
  article-title: New and future migraine therapy
  publication-title: Pharmacol Ther.
– reference: Eli Lilly and Company. A safety study of LY2951742 in participants with migraine, with or without aura. 2017. Available at: https://clinicaltrials.gov/ct2/show/NCT02614287. Accessed 29 August 2017.
– volume: 28
  start-page: 183
  issue: 2
  year: 1990
  end-page: 7
  ident: CR15
  article-title: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
  publication-title: Ann Neurol.
  doi: 10.1002/ana.410280213
– ident: CR49
– ident: CR51
– volume: e1
  start-page: 88
  year: 2017
  ident: CR58
  article-title: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the ARISE trial
  publication-title: J Neurol Neurosurg Psychiatry.
– volume: 377
  start-page: 553
  year: 2017
  end-page: 561
  ident: CR62
  article-title: Migraine
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMcp1605502
– volume: 228
  start-page: 299
  year: 1990
  end-page: 304
  ident: CR13
  article-title: Extracerebral manifestations in migraine. A peptidergic involvement?
  publication-title: J Intern Med.
  doi: 10.1111/j.1365-2796.1990.tb00236.x
– volume: 306
  start-page: 517
  issue: 9
  year: 1982
  end-page: 22
  ident: CR26
  article-title: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
  publication-title: N Engl J Med.
  doi: 10.1056/NEJM198203043060906
– volume: 13
  start-page: 1100
  issue: 11
  year: 2014
  end-page: 1107
  ident: CR31
  article-title: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70209-1
– volume: 6
  start-page: 573
  year: 2010
  end-page: 82
  ident: CR10
  article-title: CGRP and its receptors provide new insights into migraine pathophysiology
  publication-title: Nat Rev Neurol.
  doi: 10.1038/nrneurol.2010.127
– ident: CR35
– ident: CR54
– volume: 53
  start-page: 201
  issue: 4
  year: 2011
  end-page: 8
  ident: CR5
  article-title: Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine
  publication-title: Rev Neurol.
– volume: 112
  start-page: 199
  year: 2006
  end-page: 212
  ident: CR4
  article-title: New and future migraine therapy
  publication-title: Pharmacol Ther.
  doi: 10.1016/j.pharmthera.2005.04.010
– volume: 377
  start-page: 2113
  year: 2017
  end-page: 2122
  ident: CR50
  article-title: Fremanezumab for the preventive treatment of chronic migraine
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1709038
– ident: CR42
– volume: 19
  start-page: 6
  year: 2015
  ident: CR45
  article-title: TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine
  publication-title: Curr Pain Headache Rep.
  doi: 10.1007/s11916-015-0476-1
– volume: 35
  start-page: 478
  year: 2015
  end-page: 88
  ident: CR2
  article-title: Adherence to oral migraine-preventive medications among patients with chronic migraine
  publication-title: Cephalalgia.
  doi: 10.1177/0333102414547138
– volume: 13
  start-page: 885
  issue: 9
  year: 2014
  end-page: 892
  ident: CR39
  article-title: Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70128-0
– volume: 87
  start-page: 41
  year: 2016
  end-page: 48
  ident: CR48
  article-title: TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000002801
– volume: 13
  start-page: 857
  year: 2014
  end-page: 859
  ident: CR25
  article-title: Anti-CGRP antibodies: a new approach to migraine prevention
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70126-7
– volume: 83
  start-page: 958
  issue: 11
  year: 2014
  end-page: 66
  ident: CR23
  article-title: Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000000771
– volume: 8
  start-page: 1309
  year: 2013
  end-page: 23
  ident: CR24
  article-title: Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies
  publication-title: Expert Opin Drug Discov.
  doi: 10.1517/17460441.2013.826644
– volume: 00
  start-page: 1
  year: 2017
  end-page: 14
  ident: CR30
  article-title: Spotlight on Anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date
  publication-title: Clin Pharmacol Drug Dev.
– volume: 13
  start-page: 1065
  issue: 11
  year: 2014
  end-page: 7
  ident: CR63
  article-title: CGRP as a new target in prevention and treatment of migraine
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70228-5
– volume: 36
  start-page: 1
  issue: 1
  year: 2005
  end-page: 2
  ident: CR27
  article-title: Humanized antibodies and their applications
  publication-title: Methods.
  doi: 10.1016/j.ymeth.2005.02.001
– volume: 33
  start-page: 48
  issue: 1
  year: 1993
  end-page: 56
  ident: CR16
  article-title: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
  publication-title: Ann Neurol.
  doi: 10.1002/ana.410330109
– volume: 11
  start-page: 1045
  issue: 8
  year: 2016
  end-page: 1057
  ident: CR3
  article-title: Anti-CGRP monoclonal antibodies in migraine: current perspectives
  publication-title: Intern Emerg Med.
  doi: 10.1007/s11739-016-1489-4
– volume: 34
  start-page: 483
  issue: 7
  year: 2014
  end-page: 492
  ident: CR29
  article-title: Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program
  publication-title: Cephalalgia.
  doi: 10.1177/0333102413517775
– ident: CR32
– ident: CR60
– ident: CR36
– volume: 68
  start-page: 343
  year: 2007
  end-page: 9
  ident: CR1
  article-title: Migraine prevalence, disease burden, and the need for preventive therapy
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000252808.97649.21
– volume: 23
  start-page: 193
  year: 1988
  end-page: 6
  ident: CR9
  article-title: Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system
  publication-title: Ann Neurol.
  doi: 10.1002/ana.410230214
– volume: 22
  start-page: 54
  year: 2002
  end-page: 61
  ident: CR18
  article-title: CGRP may play a causative role in migraine
  publication-title: Cephalalgia.
  doi: 10.1046/j.1468-2982.2002.00310.x
– volume: 14
  start-page: 1081
  issue: 11
  year: 2015
  end-page: 1090
  ident: CR46
  article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(15)00249-5
– ident: CR43
– volume: 89
  start-page: 1237
  year: 2017
  end-page: 43
  ident: CR56
  article-title: Erenumab (AMG334) in episodic migraine. Interim analysis of an ongoing open-label study
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000004391
– volume: 79
  start-page: 886
  issue: 6
  year: 2015
  end-page: 895
  ident: CR28
  article-title: Therapeutic antibodies against CGRP or its receptor
  publication-title: Br J Clin Pharmacol.
  doi: 10.1111/bcp.12591
– volume: 88
  issue: 16 Supplement
  year: 2017
  ident: CR33
  article-title: Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of chronic migraine
  publication-title: Neurology
– volume: 9
  start-page: 9
  year: 2009
  end-page: 14
  ident: CR21
  article-title: CGRP receptors in the control of pain and inflammation
  publication-title: Curr Opin Pharmacol.
  doi: 10.1016/j.coph.2008.12.007
– ident: CR37
– ident: CR53
– volume: 304
  start-page: 129
  issue: 5922
  year: 1983
  end-page: 35
  ident: CR8
  article-title: Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing
  publication-title: Nature.
  doi: 10.1038/304129a0
– volume: 16
  start-page: 425
  year: 2017
  end-page: 34
  ident: CR57
  article-title: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(17)30083-2
– volume: 24
  start-page: 197
  issue: 3
  year: 2011
  end-page: 202
  ident: CR19
  article-title: Advances in understanding the mechanisms of migraine-type photophobia
  publication-title: Curr Opin Neurol.
  doi: 10.1097/WCO.0b013e3283466c8e
– volume: 356
  start-page: 223
  year: 2016
  end-page: 231
  ident: CR52
  article-title: Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor
  publication-title: J Pharmacol Exp Ther.
  doi: 10.1124/jpet.115.227793
– volume: 350
  start-page: 1104
  year: 2004
  end-page: 10
  ident: CR12
  article-title: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa030505
– ident: CR40
– volume: 77
  start-page: 202
  issue: 3
  year: 2005
  end-page: 213
  ident: CR22
  article-title: BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation
  publication-title: Clin Pharmacol Ther.
  doi: 10.1016/j.clpt.2004.10.001
– volume: 155
  start-page: 1093
  issue: 7
  year: 2008
  end-page: 103
  ident: CR64
  article-title: CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
  publication-title: Br J Pharmacol.
  doi: 10.1038/bjp.2008.334
– volume: 15
  start-page: 382
  issue: 4
  year: 2016
  end-page: 390
  ident: CR55
  article-title: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(16)00019-3
– volume: 37
  start-page: 560
  issue: 6
  year: 2016
  end-page: 570
  ident: CR20
  article-title: Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents
  publication-title: Cephalalgia.
  doi: 10.1177/0333102416650702
– volume: 37
  start-page: 779
  year: 2016
  end-page: 788
  ident: CR11
  article-title: Wiping out CGRP: potential cardiovascular risks
  publication-title: Trends Pharmacol Sci.
  doi: 10.1016/j.tips.2016.06.002
– ident: CR44
– volume: 14
  start-page: 1091
  issue: 11
  year: 2015
  end-page: 1100
  ident: CR47
  article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(15)00245-8
– ident: CR38
– volume: 97
  start-page: 553
  year: 2017
  end-page: 622
  ident: CR6
  article-title: Pathophysiology of migraine: a disorder of sensory processing
  publication-title: Physiol Rev.
  doi: 10.1152/physrev.00034.2015
– volume: 377
  start-page: 2123
  year: 2017
  end-page: 2132
  ident: CR59
  article-title: A controlled trial of erenumab for episodic migraine
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1705848
– volume: 15
  start-page: 347
  issue: 4
  year: 2016
  end-page: 349
  ident: CR14
  article-title: AMG 334 CGRP antibody for migraine: time to celebrate?
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(16)00040-5
– ident: CR34
– volume: 81
  start-page: 1191
  year: 2013
  end-page: 1196
  ident: CR17
  article-title: Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
  publication-title: Neurology.
  doi: 10.1212/WNL.0b013e3182a6cb72
– volume: 30
  start-page: 272
  year: 2017
  end-page: 80
  ident: CR61
  article-title: Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies
  publication-title: Curr Opin Neurol.
  doi: 10.1097/WCO.0000000000000438
– ident: CR41
– volume: 346
  start-page: 257
  issue: 4
  year: 2002
  end-page: 270
  ident: CR7
  article-title: Migraine—current understanding and treatment
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMra010917
– volume: 53
  start-page: 201
  issue: 4
  year: 2011
  ident: 10.1007/s13311-018-0622-7_bib5
  article-title: Predisposing factors affecting drop-out rates in preventive treatment in a series of patients with migraine
  publication-title: Rev Neurol.
– volume: 9
  start-page: 9
  year: 2009
  ident: 10.1007/s13311-018-0622-7_bib21
  article-title: CGRP receptors in the control of pain and inflammation
  publication-title: Curr Opin Pharmacol.
  doi: 10.1016/j.coph.2008.12.007
– ident: 10.1007/s13311-018-0622-7_bib49
– volume: 13
  start-page: 1065
  issue: 11
  year: 2014
  ident: 10.1007/s13311-018-0622-7_bib63
  article-title: CGRP as a new target in prevention and treatment of migraine
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70228-5
– ident: 10.1007/s13311-018-0622-7_bib51
– volume: 33
  start-page: 48
  issue: 1
  year: 1993
  ident: 10.1007/s13311-018-0622-7_bib16
  article-title: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats
  publication-title: Ann Neurol.
  doi: 10.1002/ana.410330109
– volume: 00
  start-page: 1
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib30
  article-title: Spotlight on Anti-CGRP monoclonal antibodies in migraine: the clinical evidence to date
  publication-title: Clin Pharmacol Drug Dev.
– volume: 79
  start-page: 886
  issue: 6
  year: 2015
  ident: 10.1007/s13311-018-0622-7_bib28
  article-title: Therapeutic antibodies against CGRP or its receptor
  publication-title: Br J Clin Pharmacol.
  doi: 10.1111/bcp.12591
– volume: 377
  start-page: 2123
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib59
  article-title: A controlled trial of erenumab for episodic migraine
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1705848
– volume: 112
  start-page: 199
  year: 2006
  ident: 10.1007/s13311-018-0622-7_bib4
  article-title: New and future migraine therapy
  publication-title: Pharmacol Ther.
  doi: 10.1016/j.pharmthera.2005.04.010
– volume: 304
  start-page: 129
  issue: 5922
  year: 1983
  ident: 10.1007/s13311-018-0622-7_bib8
  article-title: Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing
  publication-title: Nature.
  doi: 10.1038/304129a0
– volume: 88
  issue: 16 Supplement
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib33
  article-title: Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP antibody in the prevention of chronic migraine
  publication-title: Neurology
– volume: 30
  start-page: 272
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib61
  article-title: Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies
  publication-title: Curr Opin Neurol.
  doi: 10.1097/WCO.0000000000000438
– ident: 10.1007/s13311-018-0622-7_bib35
– ident: 10.1007/s13311-018-0622-7_bib42
– ident: 10.1007/s13311-018-0622-7_bib54
– volume: 14
  start-page: 1081
  issue: 11
  year: 2015
  ident: 10.1007/s13311-018-0622-7_bib46
  article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(15)00249-5
– volume: 97
  start-page: 553
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib6
  article-title: Pathophysiology of migraine: a disorder of sensory processing
  publication-title: Physiol Rev.
  doi: 10.1152/physrev.00034.2015
– volume: 356
  start-page: 223
  year: 2016
  ident: 10.1007/s13311-018-0622-7_bib52
  article-title: Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor
  publication-title: J Pharmacol Exp Ther.
  doi: 10.1124/jpet.115.227793
– volume: 77
  start-page: 202
  issue: 3
  year: 2005
  ident: 10.1007/s13311-018-0622-7_bib22
  article-title: BIBN4096BS antagonizes human α-calcitonin gene related peptide-induced headache and extracerebral artery dilatation
  publication-title: Clin Pharmacol Ther.
  doi: 10.1016/j.clpt.2004.10.001
– volume: 89
  start-page: 1237
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib56
  article-title: Erenumab (AMG334) in episodic migraine. Interim analysis of an ongoing open-label study
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000004391
– volume: 14
  start-page: 1091
  issue: 11
  year: 2015
  ident: 10.1007/s13311-018-0622-7_bib47
  article-title: Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(15)00245-8
– volume: 81
  start-page: 1191
  year: 2013
  ident: 10.1007/s13311-018-0622-7_bib17
  article-title: Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine
  publication-title: Neurology.
  doi: 10.1212/WNL.0b013e3182a6cb72
– volume: 19
  start-page: 6
  year: 2015
  ident: 10.1007/s13311-018-0622-7_bib45
  article-title: TEV-48125: a review of a monoclonal CGRP antibody in development for the preventive treatment of migraine
  publication-title: Curr Pain Headache Rep.
  doi: 10.1007/s11916-015-0476-1
– ident: 10.1007/s13311-018-0622-7_bib32
– volume: 228
  start-page: 299
  year: 1990
  ident: 10.1007/s13311-018-0622-7_bib13
  article-title: Extracerebral manifestations in migraine. A peptidergic involvement?
  publication-title: J Intern Med.
  doi: 10.1111/j.1365-2796.1990.tb00236.x
– volume: 24
  start-page: 197
  issue: 3
  year: 2011
  ident: 10.1007/s13311-018-0622-7_bib19
  article-title: Advances in understanding the mechanisms of migraine-type photophobia
  publication-title: Curr Opin Neurol.
  doi: 10.1097/WCO.0b013e3283466c8e
– ident: 10.1007/s13311-018-0622-7_bib36
– ident: 10.1007/s13311-018-0622-7_bib60
– volume: 13
  start-page: 1100
  issue: 11
  year: 2014
  ident: 10.1007/s13311-018-0622-7_bib31
  article-title: Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70209-1
– year: 2017
  ident: 10.1007/s13311-018-0622-7_bib53
  article-title: Phase 1, randomized, double-blind, placebo-controlled, single-dose and multiple-dose studies of erenumab in healthy subjects and patients with migraine.
  publication-title: Clin Pharmacol Ther.
– volume: 11
  start-page: 1045
  issue: 8
  year: 2016
  ident: 10.1007/s13311-018-0622-7_bib3
  article-title: Anti-CGRP monoclonal antibodies in migraine: current perspectives
  publication-title: Intern Emerg Med.
  doi: 10.1007/s11739-016-1489-4
– volume: 22
  start-page: 54
  year: 2002
  ident: 10.1007/s13311-018-0622-7_bib18
  article-title: CGRP may play a causative role in migraine
  publication-title: Cephalalgia.
  doi: 10.1046/j.1468-2982.2002.00310.x
– volume: 377
  start-page: 2113
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib50
  article-title: Fremanezumab for the preventive treatment of chronic migraine
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa1709038
– volume: 37
  start-page: 560
  issue: 6
  year: 2016
  ident: 10.1007/s13311-018-0622-7_bib20
  article-title: Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents
  publication-title: Cephalalgia.
  doi: 10.1177/0333102416650702
– volume: 35
  start-page: 478
  year: 2015
  ident: 10.1007/s13311-018-0622-7_bib2
  article-title: Adherence to oral migraine-preventive medications among patients with chronic migraine
  publication-title: Cephalalgia.
  doi: 10.1177/0333102414547138
– ident: 10.1007/s13311-018-0622-7_bib40
  doi: 10.1001/jamaneurol.2017.3859
– volume: 13
  start-page: 857
  year: 2014
  ident: 10.1007/s13311-018-0622-7_bib25
  article-title: Anti-CGRP antibodies: a new approach to migraine prevention
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70126-7
– ident: 10.1007/s13311-018-0622-7_bib43
– volume: 23
  start-page: 193
  year: 1988
  ident: 10.1007/s13311-018-0622-7_bib9
  article-title: Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system
  publication-title: Ann Neurol.
  doi: 10.1002/ana.410230214
– volume: 6
  start-page: 573
  year: 2010
  ident: 10.1007/s13311-018-0622-7_bib10
  article-title: CGRP and its receptors provide new insights into migraine pathophysiology
  publication-title: Nat Rev Neurol.
  doi: 10.1038/nrneurol.2010.127
– volume: 13
  start-page: 885
  issue: 9
  year: 2014
  ident: 10.1007/s13311-018-0622-7_bib39
  article-title: Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(14)70128-0
– volume: 377
  start-page: 553
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib62
  article-title: Migraine
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMcp1605502
– volume: 350
  start-page: 1104
  year: 2004
  ident: 10.1007/s13311-018-0622-7_bib12
  article-title: Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMoa030505
– volume: 155
  start-page: 1093
  issue: 7
  year: 2008
  ident: 10.1007/s13311-018-0622-7_bib64
  article-title: CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat
  publication-title: Br J Pharmacol.
  doi: 10.1038/bjp.2008.334
– volume: 34
  start-page: 483
  issue: 7
  year: 2014
  ident: 10.1007/s13311-018-0622-7_bib29
  article-title: Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the phase 1 program
  publication-title: Cephalalgia.
  doi: 10.1177/0333102413517775
– volume: 36
  start-page: 1
  issue: 1
  year: 2005
  ident: 10.1007/s13311-018-0622-7_bib27
  article-title: Humanized antibodies and their applications
  publication-title: Methods.
  doi: 10.1016/j.ymeth.2005.02.001
– ident: 10.1007/s13311-018-0622-7_bib37
– volume: e1
  start-page: 88
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib58
  article-title: A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab in migraine prevention: primary results of the ARISE trial
  publication-title: J Neurol Neurosurg Psychiatry.
– volume: 28
  start-page: 183
  issue: 2
  year: 1990
  ident: 10.1007/s13311-018-0622-7_bib15
  article-title: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
  publication-title: Ann Neurol.
  doi: 10.1002/ana.410280213
– volume: 37
  start-page: 779
  year: 2016
  ident: 10.1007/s13311-018-0622-7_bib11
  article-title: Wiping out CGRP: potential cardiovascular risks
  publication-title: Trends Pharmacol Sci.
  doi: 10.1016/j.tips.2016.06.002
– volume: 16
  start-page: 425
  year: 2017
  ident: 10.1007/s13311-018-0622-7_bib57
  article-title: Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
  publication-title: Lancet Neurol
  doi: 10.1016/S1474-4422(17)30083-2
– volume: 15
  start-page: 347
  issue: 4
  year: 2016
  ident: 10.1007/s13311-018-0622-7_bib14
  article-title: AMG 334 CGRP antibody for migraine: time to celebrate?
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(16)00040-5
– volume: 306
  start-page: 517
  issue: 9
  year: 1982
  ident: 10.1007/s13311-018-0622-7_bib26
  article-title: Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody
  publication-title: N Engl J Med.
  doi: 10.1056/NEJM198203043060906
– volume: 15
  start-page: 382
  issue: 4
  year: 2016
  ident: 10.1007/s13311-018-0622-7_bib55
  article-title: Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(16)00019-3
– ident: 10.1007/s13311-018-0622-7_bib44
– volume: 346
  start-page: 257
  issue: 4
  year: 2002
  ident: 10.1007/s13311-018-0622-7_bib7
  article-title: Migraine—current understanding and treatment
  publication-title: N Engl J Med.
  doi: 10.1056/NEJMra010917
– volume: 68
  start-page: 343
  year: 2007
  ident: 10.1007/s13311-018-0622-7_bib1
  article-title: Migraine prevalence, disease burden, and the need for preventive therapy
  publication-title: Neurology
  doi: 10.1212/01.wnl.0000252808.97649.21
– volume: 8
  start-page: 1309
  year: 2013
  ident: 10.1007/s13311-018-0622-7_bib24
  article-title: Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies
  publication-title: Expert Opin Drug Discov.
  doi: 10.1517/17460441.2013.826644
– volume: 87
  start-page: 41
  year: 2016
  ident: 10.1007/s13311-018-0622-7_bib48
  article-title: TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000002801
– volume: 83
  start-page: 958
  issue: 11
  year: 2014
  ident: 10.1007/s13311-018-0622-7_bib23
  article-title: Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
  publication-title: Neurology.
  doi: 10.1212/WNL.0000000000000771
– ident: 10.1007/s13311-018-0622-7_bib38
– ident: 10.1007/s13311-018-0622-7_bib34
– ident: 10.1007/s13311-018-0622-7_bib41
SSID ssj0053398
Score 2.4564326
SecondaryResourceType review_article
Snippet Calcitonin gene-related peptide (CGRP) is 37-amino-acid neuropeptide, crucially involved in migraine pathophysiology. Four monoclonal antibodies (mAbs)...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
springer
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 324
SubjectTerms Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - therapeutic use
Biomedical and Life Sciences
Biomedicine
Calcitonin
Calcitonin gene-related peptide
Calcitonin Gene-Related Peptide - metabolism
Calcitonin Gene-Related Peptide Receptor Antagonists - immunology
Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use
Central nervous system
Clinical trials
Clinical Trials as Topic
Efficacy
Headache
Humans
Immunoglobulins
Migraine
Migraine Disorders - drug therapy
Migraine Disorders - immunology
Migraine Disorders - physiopathology
Monoclonal antibodies
Neurobiology
Neurology
Neurosciences
Neurosurgery
Peptides
Review
Safety
Tolerability
Treatment Outcome
SummonAdditionalLinks – databaseName: SpringerLINK - Czech Republic Consortium
  dbid: AGYKE
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB7BVuJx4P0IFGQkTlSpEjt2Em5V1aUCLephK5VT5PgBK6Jk1d0IlV_POImzlMKinmNbsfNl_I1m5huAtyYTNpUlDalJ0UERxoSZTFSoKdexNpnMM1ecPPssjk-Tj2f8bKjjXvlsdx-S7Cz1ptiNsa4GLAsjgR5UehN2uPNPJrBz8OHLpyNvgJHAdC1wkZqwEB0c5oOZf1vkX9fRVbp5NWtyDJ3ehdttvZQXP2RV_XY7Te_D3O-rT0r5vt-uy3318w_Jx2tu_AHcG9gqOejh9RBumPoR3JoN8fjHsESUkb6d5QVpLEEL0aiq6ebU60XZuBzF92TaqHZFmpocykqhCakXNXF612GXimc0OXG5NdoQZNDk5LzBT191xVtktvjqelgYMu_VD57A6fRofngcDj0cQsUTsQ5zy6lEzhdnpXJ9sozjQ0wZquKEJ5qnFEGENsEyIzTPqEYPB70qyZQVjHLJnsKkbmrzHIjVFs2rjWJVikRGNrcZi3RuneJfwpUIIPKfslCDwLnrs1EVG2lmd5IFnmThTrJIA3g3Tln26h7bBlOPj8KXraKhLfDu2TZp1yOpGKzDqqBIrJA4sjwO4M34GP9rF6yRtWnafkzKnNxeAM964I2vSHOBXm6eBJBeguQ4wGmGX35SL7512uE8Z0jhcc09j7XNa23ZxN6I7_-f04trrf0S7tAO2i4Zahcm6_PWvEKety5fD__1L6DwRfA
  priority: 102
  providerName: Springer Nature
– databaseName: Unpaywall
  dbid: UNPAY
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB6VVIJy4E0JFLRInKic2rv22uZWRUQVUqocGqmcrPU-SoS1jlpbqPx6Zv0KpRCEOO9D9vrz7DeamW8A3umEm1jk1KM6RgeFa-0lIpSeopEKlE5Emrji5PkpP1mGn86j8x2Y9rUwTbZ7H5JsaxqcSpOtjtbKHG0K3xhr6sESz-foTcUTHL0Du9xFmUawuzxdHH92rlYSO7XMRnEPmQrz0N9hfWzzd_v86Xa6zT5vJ1EOkdT7cK-2a3H9TRTFT5fV7CGo_jXbHJWvk7rKJ_L7LwqQ_3kOj-BBR2bJcYu-x7Cj7RO4O-_C9U9hjSAkbbfLa1IaggaklEXZrLHVKi9dCuMHMitlfUVKS6aikGhh7MoSJ4ftNZl6WpGFS71RmiDBJovLEpFRNLVdZL66cC0uNDlrxRGewXL28Wx64nUtHjwZhbzyUhNRgZQwSHLp2mhpR5eY1FQGYRSqKKaIMTQZhmmuooQqdIDQ6RJMGs5oJNhzGNnS6hdAjDJofY0fyJyHwjepSZivUuMEAcNI8jH4_afNZKd_7tpwFNlGudmdZoanmbnTzOIxvB-WrFvxj22TaY-XrK9qRTuc4dW0bdFBj6ysMx5XGUXehbySpcEY3g7D-Nu7WI6wuqzbOTFzanxj2G-BODwiTTk6wWk4hvgGRIcJTlL85ohdfWmkxaOUIcPHPQ977G0ea8tLHA54__s5vfyn2a9gjzbwdrlSBzCqLmv9Gmlglb_pfvMfxuJRZw
  priority: 102
  providerName: Unpaywall
Title The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy
URI https://www.clinicalkey.com/#!/content/1-s2.0-S1878747923015647
https://link.springer.com/article/10.1007/s13311-018-0622-7
https://www.ncbi.nlm.nih.gov/pubmed/29616494
https://www.proquest.com/docview/2021172391
https://www.proquest.com/docview/2021731341
https://pubmed.ncbi.nlm.nih.gov/PMC5935651
https://link.springer.com/content/pdf/10.1007/s13311-018-0622-7.pdf
UnpaywallVersion publishedVersion
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1878-7479
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053398
  issn: 1878-7479
  databaseCode: AKRWK
  dateStart: 20070101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVLSH
  databaseName: SpringerLink Journals
  customDbUrl:
  mediaType: online
  eissn: 1878-7479
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053398
  issn: 1878-7479
  databaseCode: AFBBN
  dateStart: 20040101
  isFulltext: true
  providerName: Library Specific Holdings
– providerCode: PRVAQN
  databaseName: PubMed Central (Free e-resource, activated by CARLI)
  customDbUrl:
  eissn: 1878-7479
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053398
  issn: 1878-7479
  databaseCode: RPM
  dateStart: 20070101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 1878-7479
  dateEnd: 20231031
  omitProxy: true
  ssIdentifier: ssj0053398
  issn: 1878-7479
  databaseCode: 7X7
  dateStart: 20070101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1878-7479
  dateEnd: 20231031
  omitProxy: true
  ssIdentifier: ssj0053398
  issn: 1878-7479
  databaseCode: BENPR
  dateStart: 20070101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVAVX
  databaseName: SpringerLINK - Czech Republic Consortium
  customDbUrl:
  eissn: 1878-7479
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0053398
  issn: 1878-7479
  databaseCode: AGYKE
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: http://link.springer.com
  providerName: Springer Nature
– providerCode: PRVAVX
  databaseName: SpringerLink Journals (ICM)
  customDbUrl:
  eissn: 1878-7479
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0053398
  issn: 1878-7479
  databaseCode: U2A
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: http://www.springerlink.com/journals/
  providerName: Springer Nature
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9swEBdbC_t4GPvq5q0rGuxpRWBLtmzvZWQlWVlICKVh6ZOR9bEFjJ01CaP__e78lZWy7MkEScH23Um_8939jpAPNpEuVjln3MbgoEhrWaJCzQyPTGBsotIEi5MnU3k-D78tokX7wW3dplV2e2K9UZtK4zdydNIDOGxFGnxe_WLYNQqjq20LjfvkMACoglodL3qHC5BM3QsXMIpg4OmILqpZl84JUVeUJcyX4I_F_zqX7uLOu-mTfQz1MXm4LVfq5rcqir-OqdFT8qTFl3TQKMQzcs-Wz8mDSRtBf0FWoBe0aUB5QytHwaYrXVT1mnKzzCvMKvxER5XermlV0jNVaDD6cllSZKhmdfKcNXSG2TDGUsC8dHZdgbCKutyKTpY_sOuEpZcNX8FLMh8NL8_OWdt1gekolBuWuogrQGlBkmvsbGURwQhtuQ7CKDRRzEHsYMVOWGmihBvwScAPUkI7KXikxBE5KKvSvibUGQcbovMDnctQ-S51ifBN6pCjL4y09IjfvfNMt5Tk2BmjyHZkyiimDMSUoZiy2CMf-yWrho9j32TeCTLrCk1ha8zgtNi36LgTedba8zrbaZ9H3vfDYIkYXlGlrbbNnFggQZ5HXjUa0t8iTyX4pWnokfiW7vQTkOX79ki5_FmzfUepANAN_3naadnutvY8xGmviP9_T2_2P_Jb8ojXhoL5SsfkYHO9te8Aim3yk9reTsjh4OvVeIjX8cX3MVy_DKezCxid8wH8mk9ng6s_vos0Dg
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIlF6QLwKLgUWCS5UluxdP5EQQoUopU3VQyrlZtb7gEiWHZpEVf4Uv5EZv0JVEU49e3fl9Xw7-43nBfDWJJGNZc5dbmI0UCJj3EQGytU81L42iUwTSk4enUXDi-DbJJxswe8uF4bCKjudWCtqXSn6R05Guo-XrUj9T7NfLnWNIu9q10KjgcWJWV2hyTb_ePwF5fuO88HX8dHQbbsKuCoMooWb2pBLZCF-kivq3GTohhbKcOUHYaDDmOO2EKVWmEiHCdfIuZHnS6FsJHgoBa57B-4GwguoVn886Q08ZE51713kRMJFy0p0XtQ6VU-IOoMtcb0I7b_4X_fgTZ57M1yz99nuws6ynMnVlSyKv67FwUN40PJZ9rkB4CPYMuVjuDdqPfZPYIY4ZE3DyxWrLEMdUqmiqueUi2leURTjBzao1HLOqpIdyUKhkimnJaOK2G4drGc0O6foG20Ycmx2flkhOIo6vYuNpj-oy4Vh46Y-wlO4uBV57MF2WZXmOTCrLSpg6_kqjwLp2dQmwtOppZqAQagiB7zum2eqLYFOnTiKbF28mcSUoZgyElMWO_C-nzJr6n9sGsw7QWZdYiuq4gxvp02TDjqRZ63-mGdrtDvwpn-MJ5_cObI01bIZEwsqyOfAswYh_SvyNEI7OA0ciK9hpx9AVcWvPymnP-vq4mEqkOTjmocdytavtWEThz0Q__-d9jdv-TXsDMej0-z0-OzkBdzn9aGhWKkD2F5cLs1LpIGL_FV99hh8v-3D_gfK_Gf4
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEB6VIhU4IN4YCiwSXKgs7F0_kRBCLVFLSZVDK-VmNvuASJYdmkRV_hq_jpn1I1QV4dSzd1dez7ez33heAG9MlthUTrjPTYoGSmKMn8lI-ZrHOtQmk3lGycnDk-TwLPo6jsdb8LvLhaGwyk4nOkWta0X_yMlID_GyFXn43rZhEaODwafZL586SJGntWun0UDk2Kwu0Hybfzw6QFm_5Xzw5XT_0G87DPgqjpKFn9uYS2QkYTZR1MXJ0G0tlOEqjOJIxynHLSJirTCJjjOukX8j55dC2UTwWApc9wbcTEUkKJwsHffGHrIo14cX-ZHw0coSnUfVpe0J4bLZMj9I0BZM_3UnXuW8V0M3e__tHbi1rGZydSHL8q8rcnAP7rbcln1uwHgftkz1AHaGrff-IcwQk6xpfrlitWWoT2pV1m5OtZhOaopo_MAGtVrOWV2xfVkqVDjVtGJUHdt3gXtGsxFF4mjDkG-z0XmNQCldqhcbTn9QxwvDTptaCY_g7Frk8Ri2q7oyT4FZbVEZ2yBUkySSgc1tJgKdW6oPGMUq8SDovnmh2nLo1JWjLNaFnElMBYqpIDEVqQfv-imzphbIpsG8E2TRJbmiWi7wpto0abcTedHqknmxRr4Hr_vHqAXItSMrUy-bMamg4nwePGkQ0r8izxO0ifPIg_QSdvoBVGH88pNq-tNVGo9zgYQf19zrULZ-rQ2b2OuB-P_v9Gzzll_BDh7z4tvRyfFzuM3dmaGwqV3YXpwvzQtkhIvJS3f0GHy_7rP-Bx0tbDM
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEB6VVIJy4E0JFLRInKic2rv22uZWRUQVUqocGqmcrPU-SoS1jlpbqPx6Zv0KpRCEOO9D9vrz7DeamW8A3umEm1jk1KM6RgeFa-0lIpSeopEKlE5Emrji5PkpP1mGn86j8x2Y9rUwTbZ7H5JsaxqcSpOtjtbKHG0K3xhr6sESz-foTcUTHL0Du9xFmUawuzxdHH92rlYSO7XMRnEPmQrz0N9hfWzzd_v86Xa6zT5vJ1EOkdT7cK-2a3H9TRTFT5fV7CGo_jXbHJWvk7rKJ_L7LwqQ_3kOj-BBR2bJcYu-x7Cj7RO4O-_C9U9hjSAkbbfLa1IaggaklEXZrLHVKi9dCuMHMitlfUVKS6aikGhh7MoSJ4ftNZl6WpGFS71RmiDBJovLEpFRNLVdZL66cC0uNDlrxRGewXL28Wx64nUtHjwZhbzyUhNRgZQwSHLp2mhpR5eY1FQGYRSqKKaIMTQZhmmuooQqdIDQ6RJMGs5oJNhzGNnS6hdAjDJofY0fyJyHwjepSZivUuMEAcNI8jH4_afNZKd_7tpwFNlGudmdZoanmbnTzOIxvB-WrFvxj22TaY-XrK9qRTuc4dW0bdFBj6ysMx5XGUXehbySpcEY3g7D-Nu7WI6wuqzbOTFzanxj2G-BODwiTTk6wWk4hvgGRIcJTlL85ohdfWmkxaOUIcPHPQ977G0ea8tLHA54__s5vfyn2a9gjzbwdrlSBzCqLmv9Gmlglb_pfvMfxuJRZw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Biology+of+Monoclonal+Antibodies%3A+Focus+on+Calcitonin+Gene-Related+Peptide+for+Prophylactic+Migraine+Therapy&rft.jtitle=Neurotherapeutics&rft.au=Raffaelli%2C+Bianca&rft.au=Reuter%2C+Uwe&rft.date=2018-04-01&rft.pub=Springer+Nature+B.V&rft.issn=1933-7213&rft.eissn=1878-7479&rft.volume=15&rft.issue=2&rft.spage=324&rft.epage=335&rft_id=info:doi/10.1007%2Fs13311-018-0622-7&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1878-7479&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1878-7479&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1878-7479&client=summon